文献速递妇科

FIGO I期子宫内膜样癌前哨淋巴结活检的生存结局

Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
PubMed 文献 · Gynecol Oncol · 2021-03-24

基于美国国家癌症数据库(NCDB)2012—2015年FIGO I期子宫内膜样癌接受微创子宫切除的患者,比较前哨淋巴结活检(SLNBx)与系统性淋巴结清扫(LND)的总生存。共13,010例,SLNBx组生存不劣于LND组(HR 0.99,95%CI 0.80–1.21),中高危和特定中危亚组亦未见生存受损。

要点

  • FIGO I期子宫内膜样癌SLNBx与系统性LND总生存无显著差异。
  • LND组接受放疗和化疗的比例显著高于SLNBx组。
  • 中高危和中危亚组中SLNBx均未显示生存劣势。

核心结论

  • FIGO I期子宫内膜样癌行子宫切除的患者中,前哨淋巴结活检对生存无负面影响。

研究设计与样本

  • 回顾性队列研究,数据来自美国国家癌症数据库(NCDB)。
  • 纳入2012—2015年病理分期I期子宫内膜样癌、接受微创子宫切除且随访至少1个月的患者。
  • 共13,010例,其中系统性淋巴结清扫(LND,至少切除20枚淋巴结)9,861例(75.8%),前哨淋巴结活检(SLNBx)3,149例(24.2%)。

主要发现

  • LND组接受放疗的比例为27.4%,SLNBx组为19.3%(p < 0.001)。
  • LND组接受化疗的比例为13%,SLNBx组为8.7%(p < 0.001)。
  • 控制年龄、种族、保险状态、肌层浸润深度、肿瘤分级、肿瘤大小、淋巴血管间隙浸润及放疗后,SLNBx与更差生存无关(HR 0.99,95%CI 0.80–1.21)。
  • 基于GOG-99标准的高中危患者中,控制混杂因素后SLNBx与更差生存无关(HR 1.07,95%CI 0.80–1.44)。
  • 未接受外照射放疗或化疗的中危患者中,控制混杂因素后SLNBx与更差生存无关(HR 1.58,95%CI 0.94–2.65)。

临床怎么用

  • FIGO I期子宫内膜样癌微创子宫切除时可考虑前哨淋巴结活检替代系统性淋巴结清扫。
  • SLNBx组接受辅助放疗和化疗的比例较低,或可减少治疗相关并发症。

局限性

  • 回顾性研究,存在选择偏倚和混杂因素可能。
  • LND定义基于至少切除20枚淋巴结,可能影响组间可比性。
  • 中危亚组HR的95%CI较宽且跨1,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Investigate the overall survival of patients with FIGO stage I endometrioid endometrial carcinoma who underwent sentinel lymph node biopsy (SLNBx). METHODS: Patients diagnosed between 2012 and 2015 with pathological stage I endometrioid endometrial carcinoma who underwent minimally invasive hysterectomy and had at least one month of follow-up were identified in the National Cancer Database (NCDB). Patients who underwent SLNBx or systematic lymphadenectomy (LND) (defined as at least 20 lymph nodes removed) were selected. Overall survival (OS) was evaluated following generation of Kaplan-Meier curves and compared with the log-rank test. A Cox model was constructed to evaluate survival after controlling for confounders. RESULTS: A total of 13,010 patients with endometrioid endometrial carcinoma who met the inclusion criteria were identified; 9861 (75.8%) and 3149 (24.2%) patients had systematic LND and SLNBx, respectively. Patients who had LND were more likely to receive radiation therapy (27.4% vs 19.3%, p < 0.001) and chemotherapy (13% vs 8.7%, p < 0.001) compared to those who had SLNBx. After controlling for patient age, race, insurance status, depth of myometrial invasion, tumor grade, tumor size, presence of lymph-vascular invasion and receipt of radiation therapy, the performance of SLNBx was not associated with worse survival (HR: 0.99, 95% CI: 0.80, 1.21). For high-intermediate risk patients (based on GOG-99 criteria) after controlling for confounders, performance of SLNBx was not associated with worse survival (HR: 1.07, 95% CI: 0.80, 1.44). For intermediate risk patients who did not receive external beam radiation therapy or chemotherapy after controlling for confounders, performance of SLNBx was not associated with worse survival (HR: 1.58, 95% CI: 0.94, 2.65). CONCLUSIONS: SLNBx had no negative impact on the survival of patients with FIGO stage I endometrioid endometrial carcinoma who undergo hysterectomy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nasioudis D, Byrne M, Ko EM, et al. Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma. Gynecol Oncol. 2021. PMID: 33771397. doi:10.1016/j.ygyno.2021.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。